Bavarian Nordic's PRV goes for $160M; Biomea to advance GLP-1 into trials

Plus, news about, Camurus and Pelage Pharmaceuticals: Bavarian Nordic to sell its priority review voucher: The Danish pharma company will hand over the PRV to an undisclosed buyer for $160 million ...

Related Posts

Sanofi touts $20B investment in US over five years

May 14, 2025  0

As a challenging first half nears a close, biopharma un...

May 30, 2025  0

Exclusive: Brooklyn Health raises $6.5M to standardize ...

May 27, 2025  0

Comments

Name

Email

Comment

Post Comment